Frequency Therapeutics initiated with a Buy at Chardan
The Fly

Frequency Therapeutics initiated with a Buy at Chardan

Chardan analyst Daniil Gataulin initiated coverage of Frequency Therapeutics with a Buy rating and $7 price target. The analyst cites the potential of the company’s progenitor cell activation approach in treating degenerative diseases, with the initial focus on sensorineural hearing loss, for the Buy rating. Frequency’s lead compound, FX-322, is in the later stages of a Phase 2b trial in patients with noise induced hearing loss and sudden sensorineural hearing loss, with data expected in Q1 of 2023, Gataulin tells investors in a research note.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on FREQ:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App